Related by context. Frequent words. (Click for all words.) 55 diabetic neuropathic pain 54 tocilizumab 53 Major Depressive Disorder 52 mg BID 52 pramipexole 52 bosentan 52 candesartan 52 JANUVIA 52 tiotropium 52 randomized Phase III 51 mg doses 51 cardiovascular morbidity 51 tolerability 51 vicriviroc 51 Phase 2a clinical 51 lubiprostone 51 LEVADEX 51 phase IIa 50 Phase IIa clinical 50 Secondary endpoints 50 phase IIb 50 lacosamide 50 plus methotrexate 50 depressive symptoms 50 calcium supplementation 50 dose cohorts 50 blinded placebo controlled 50 Phase 1a 50 ACTEMRA 49 Phase 2a trial 49 tolerated dose MTD 49 ADHD symptoms 49 Duloxetine 49 COPAXONE R 49 PROMACTA 49 safety tolerability 49 Phase 1b 49 pharmacokinetic profile 49 PANSS 49 mg dose 49 Efficacy 49 randomized placebo controlled 48 FOSRENOL R 48 blind randomized placebo 48 randomized controlled trial 48 pharmacodynamics 48 pharmacodynamic 48 aripiprazole 48 antihypertensive medications 48 Phase IIa trial 48 blind placebo controlled 48 adalimumab 48 hypertensive patients 48 myelodysplastic syndromes MDS 48 Phase IIb clinical 48 Cochrane Database 48 placebo controlled 48 Phase 1b clinical 47 placebo controlled trials 47 Phase 2b 47 sunitinib 47 Phase 2b study 47 investigational oral 47 peginterferon alfa 2b 47 phase 2a 47 QoL 47 bronchial thermoplasty 47 double blind placebo 47 relapsing remitting MS 47 bipolar depression 47 telmisartan 47 secondary endpoint 47 CAPRISA 47 randomized controlled 47 relapsing remitting multiple sclerosis 47 Torisel 47 investigational compound 47 multicentre 47 donepezil 47 dose regimens 47 composite endpoint 47 multicenter randomized double 46 single ascending dose 46 multiple ascending dose 46 primary efficacy endpoint 46 dabigatran etexilate 46 Phase 2b clinical 46 Zerenex 46 mcg kg 46 dosing schedules 46 noninferiority 46 opioid induced constipation 46 dose limiting toxicities 46 PEG Interferon lambda 46 safety tolerability pharmacokinetics 46 Systematic Reviews 46 Phase 2b trial 46 escitalopram 46 Phenoptin 46 prospective cohort 46 Phase 2a